Related Experiment Videos
Mantle cell lymphoma
1Department of Internal Medicine, Division of Hematology/Oncology, Box 800716, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
Current Treatment Options in Oncology
|June 12, 2002
Summary
Mantle cell lymphoma (MCL) is an aggressive cancer with poor prognosis. Current treatments offer limited survival benefits, highlighting the need for clinical trials and novel therapeutic strategies.
Area of Science:
- Hematology
- Oncology
- Cancer Research
Background:
- Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin's lymphoma.
- Current chemotherapeutic approaches for MCL are incurable, with median survival around 3 years.
- There is no established standard of care, emphasizing the importance of clinical trials.
Purpose of the Study:
- To review current treatment approaches for Mantle Cell Lymphoma.
- To discuss the efficacy and limitations of existing therapies.
- To underscore the significance of clinical trials for patients with MCL.
Main Methods:
- Review of existing literature on Mantle Cell Lymphoma treatment.
- Analysis of response rates and survival data for various therapeutic regimens.
- Evaluation of stem cell transplantation and novel agents.
Main Results:
- Chemotherapy regimens show response rates of 50-70% but do not prevent disease progression.
- Autologous stem cell transplant improves progression-free survival but not overall survival.
- Allogeneic transplant shows promise in young patients; agents like rituximab, fludarabine, and cladribine lack survival advantages over combination chemotherapy.
Conclusions:
- Mantle cell lymphoma remains an incurable malignancy with current standard treatments.
- Clinical trial enrollment is crucial for patients with MCL due to the lack of a clear standard of care.
- While some treatments prolong progression-free survival, none have demonstrated a significant overall survival benefit.